	US 12,336,973 B2
	Cancer therapeutic compositions and methods targeting DNAse1L3
Michael Gough, Portland, OR (US); Marka Crittenden, Portland, OR (US); and Tiffany Blair, Portland, OR (US)
Assigned to Providence Health & Services—Oregon, Portland, OR (US); and Oregon Health & Science University, Portland, OR (US)
Appl. No. 18/044,066
Filed by Providence Health & Services—Oregon, Portland, OR (US); and Oregon Health & Science University, Portland, OR (US)
PCT Filed Sep. 24, 2021, PCT No. PCT/US2021/051942 § 371(c)(1), (2) Date Mar. 3, 2023, PCT Pub. No. WO2022/067032, PCT Pub. Date Mar. 31, 2022.
Claims priority of provisional application 63/083,645, filed on Sep. 25, 2020.
Prior Publication US 2023/0241015 A1, Aug. 3, 2023
Int. Cl. A61K 31/198 (2006.01); A61K 31/53 (2006.01); A61K 31/7105 (2006.01); A61K 31/727 (2006.01); A61P 35/00 (2006.01); C12N 15/113 (2010.01)

CPC A61K 31/198 (2013.01) [A61K 31/53 (2013.01); A61K 31/7105 (2013.01); A61K 31/727 (2013.01); A61P 35/00 (2018.01); C12N 15/1137 (2013.01)]

14 Claims

1. A method for treating a subject with pancreatic carcinoma or colorectal adenocarcinoma, comprising:

Administering to the subject at least one dose of an effective amount of radiation therapy; and administering to the subject at least one dose of an effective amount of a small molecule inhibitor of DNAse1L3, wherein the small molecule inhibitor of DNAse1L3 is administered to the subject systematically and wherein the small molecule inhibitor is Fmoc-d-cyclohexylalanine (FCA), and wherein the radiation therapy and the inhibitor of DNAse1L3 are administered in either order.